Overview
- The service offers personalized plans managed by licensed providers, with prescription options such as estradiol in pill, patch, or cream form and progesterone for eligible patients.
- Shares rose roughly 12% on Wednesday with about 29 million shares traded, marking one of the stock’s heaviest-volume sessions of the year.
- Hers now serves more than 500,000 subscribers, and management projects the segment will exceed $1 billion in annual revenue in 2026.
- CEO Andrew Dudum sold about $11 million in stock on Thursday after the rally, according to a regulatory filing.
- Regulatory scrutiny from the FDA and a reported FTC probe continues to overhang the story, while Wall Street views remain split with some upgrades contrasted by a Bank of America Sell rating at $28.